BioXcel Therapeutics Inc. has released a presentation highlighting the commercial potential of IGALMI® (BXCL501) for the treatment of agitation associated with bipolar disorders and schizophrenia in both institutional and at-home settings. The presentation outlines significant market expansion opportunities, indicating an estimated 86 million addressable at-home agitation episodes annually for bipolar and schizophrenia patients. Clinical trial data from the SERENITY At-Home study demonstrated that IGALMI provided a significant treatment benefit over placebo across varying severity levels of agitation episodes. The safety profile in the at-home setting was consistent with previous findings, with no patients discontinuing due to treatment-emergent adverse events (TEAEs), and no serious adverse events, falls, or syncope reported. Most adverse events were mild, and tolerability remained stable with repeated dosing. The presentation also notes that, currently, there are no approved treatments for agitation in these populations, with existing therapies often used off-label. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.